Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $20,259.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 900 shares of Enliven Therapeutics stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $22.51, for a total value of $20,259.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.15, for a total transaction of $74,202.50.
• On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.89, for a total transaction of $130,672.50.
• On Monday, October 28th, Benjamin Hohl sold 6,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $28.56, for a total transaction of $178,500.00.
• On Friday, October 18th, Benjamin Hohl sold 814 shares of Enliven Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $24,420.00.
• On Friday, October 4th, Benjamin Hohl sold 10,218 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.51, for a total value of $281,097.18.
• On Monday, October 7th, Benjamin Hohl sold 1,270 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total value of $34,937.70.

Enliven Therapeutics Price Performance

NASDAQ:ELVN opened at $23.90 on Friday. Enliven Therapeutics, Inc. has a 1-year low of $10.90 and a 1-year high of $30.03. The business has a 50 day moving average of $25.09 and a 200 day moving average of $24.28. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of -12.58 and a beta of 1.02.

Institutional Investors Weigh In On Enliven Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp raised its position in Enliven Therapeutics by 49.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock worth $2,667,000 after purchasing an additional 37,632 shares during the period. Rhumbline Advisers grew its stake in shares of Enliven Therapeutics by 29.9% during the second quarter. Rhumbline Advisers now owns 49,627 shares of the company’s stock valued at $1,160,000 after buying an additional 11,420 shares during the last quarter. Quest Partners LLC increased its holdings in shares of Enliven Therapeutics by 87.3% in the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after buying an additional 742 shares during the period. American Century Companies Inc. lifted its stake in shares of Enliven Therapeutics by 44.7% in the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock valued at $646,000 after acquiring an additional 8,540 shares during the last quarter. Finally, Nicholas Investment Partners LP purchased a new stake in Enliven Therapeutics during the 2nd quarter valued at about $1,310,000. 95.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ELVN has been the subject of several recent analyst reports. Robert W. Baird boosted their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, November 15th. HC Wainwright reissued a “buy” rating and issued a $37.00 price target on shares of Enliven Therapeutics in a research note on Tuesday, October 1st. Finally, BTIG Research assumed coverage on shares of Enliven Therapeutics in a report on Friday, December 13th. They issued a “buy” rating and a $42.00 price target on the stock. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $38.25.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.